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Magnetic resonance detects metabolic changes
associated with chemotherapy-induced apoptosis
SM Ronen1, F DiStefano2, CL McCoy6, D Robertson3, TAD Smith4, NM Al-Saffar1, J Titley2, DC Cunningham5,
JR Griffiths6, MO Leach1 and PA Clarke2
Cancer Research Campaign (CRC), 1Clinical Magnetic Resonance Research Group, 2CRC Centre for Cancer Therapeutics, 3Electron Microscopy Unit,
4Department of Nuclear Medicine, Institute of Cancer Research, 5Royal Marsden Hospital, Down Road, Sutton, Surrey SM2 5PT, UK; 6CRC Biomedical
Magnetic Resonance Research Group, St George’s Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK
Summary Apoptosis was induced by treating L1210 leukaemia cells with mechlorethamine, and SW620 colorectal cells with doxorubicin.
The onset and progression of apoptosis were monitored by assessing caspase activation, mitochondrial transmembrane potential,
phosphatidylserine externalization, DNA fragmentation and cell morphology. In parallel, 31P magnetic resonance (MR) spectra of cell extracts
were recorded. In L1210 cells, caspase activation was detected at 4 h. By 3 h, the MR spectra showed a steady decrease in NTP and NAD,
and a significant build-up of fructose 1,6-bisphosphate (F-1,6-P) dihydroxyacetonephosphate and glycerol-3-phosphate, indicating
modulation of glycolysis. Treatment with iodoacetate also induced a build-up of F-1,6-P, while preincubation with two poly(ADP-ribose)
polymerase inhibitors, 3-aminobenzamide and nicotinamide, prevented the drop in NAD and the build-up of glycolytic intermediates. This
suggested that our results were due to inhibition of glyceraldehyde-3-phosphate dehydrogenase, possibly as a consequence of NAD
depletion following poly(ADP-ribose) polymerase activation. Doxorubicin treatment of the adherent SW620 cells caused cells committed to
apoptosis to detach. F-1,6-P was observed in detached cells, but not in treated cells that remained attached. This indicated that our
observations were not cell line- or treatment-specific, but were correlated with the appearance of apoptotic cells following drug treatment. The
31P MR spectrum of tumours responding to chemotherapy could be modulated by similar effects.
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Article no. bjoc.1998.0459Apoptosis is an active process of cell death characterized by
distinct morphological and molecular changes which can be
induced by many varied stimuli, including chemotherapeutic
treatment of tumour cells (Hickman, 1992). A recent study of
breast tru-cut tumour biopsies has demonstrated a good correlation
between the detection of increased apoptosis early following
chemotherapy and subsequent response to treatment (Ellis et al,
1997). Furthermore, the response of tumours to chemotherapy can
be influenced by the expression of genes controlling the apoptotic
process (White, 1996): in diffuse large cell lymphoma, for
example, expression of the apoptosis inhibitor bcl-2, has been
correlated with a poor prognosis (Hill et al, 1996). Thus the ability
to detect or monitor apoptosis may be an important factor in plan-
ning patient care.
Magnetic resonance spectroscopy (MRS) is a technique that
yields metabolic and bioenergetic information from cells or tissues
in a dynamic, non-invasive and non-destructive manner. It can
therefore be used for monitoring tumour progression or response
to treatment. In this context, the identification of MR-detectable
signals that are correlated with programmed cell death is impor-
tant. In vivo 31P MRS studies of apoptosis have been limited, with
preliminary reports describing a significant decrease in the
phospholipid precursor phosphoethanolamine in non-Hodgkin’sReceived 1 October 1998
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Accepted 27 November 1998
Correspondence to: SM Ronenlymphoma patients who responded to treatment (Negendank et al,
1996). Using 31P MRS in vitro, a decrease in the phosphomono-
ester peak, composed of phosphoethanolamine and phospho-
choline, was reported in dexamethasone-treated leukaemia lines
(Adebodun and Post, 1994), while others have reported an
increase in phosphocholine signal following tumour necrosis
factor (TNF)-induced apoptosis in neutrophils (Nunn et al, 1996).
In the leukaemia cells a steady decrease in nucleoside triphosphate
(NTP) following genotoxic damage was detected (Adebodun and
Post, 1994), whereas in doxorubicin-treated breast cancer cells this
was preceded by a transient increase in adenosine 5¢ -triphosphate
(ATP) (Neeman et al, 1990).
In light of the diversity of reported metabolic changes observed
by MRS, we set out to investigate the temporal relationship
between 31P MR-detected metabolic changes and some of the
biological indicators of apoptosis. Our goal was to identify
possible changes in the MRS spectra of apoptosing cells and
to correlate these changes with known events leading to cell
death following chemotherapeutic treatment. Here, we describe
31P MRS data obtained both from L1210 murine lymphocytic
leukaemia cells treated with the alkylating nitrogen mustard
mechlorethamine (HN2) and from SW620 human colorectal
cancer cells treated with the anthracyclin doxorubicin. Despite the
differences between the two model systems, we show similar
MRS-detectable signals from cells dying by apoptosis. We demon-
strate that, in L1210 cells, these MRS signals occur relatively early
in the apoptotic process, and propose a possible mechanism
explaining our MR observations.1035
1036 SM Ronen et alMATERIALS AND METHODS
Reagents were obtained from Sigma or Gibco UK unless other-
wise specified.
Cell culture and treatment
L1210 cells were cultured in suspension in RPMI-1640 supple-
mented with 10% horse serum, 2 mM L-glutamine, 50 U ml–1 peni-
cillin and 50 m g ml–1 streptomycin in 5% carbon dioxide. SW620
cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (FCS), with
other conditions as above. Cell viability was determined by trypan
blue exclusion.
For investigations of apoptosis, L1210 cells were treated with
50 m M HN2 and SW620 cells were treated with 1 m M doxorubicin.
Cells were treated by replacing the normal growth medium with
medium supplemented with the appropriate drug. To inhibit
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cells were
treated with 250 m M iodoacetate. Protein kinase C activity was
inhibited by pre-incubating for 1 h with 100 nM staurosporine.
Poly(ADP-ribose)polymerase (PARP) activity was blocked by
pre-incubating for 1 h with 15 mM nicotinamide or 10 mM 3-
aminobenzamide (Biomol).
Morphology
A total of 2 · 106 cells were fixed in 2% glutaraldehyde in 0.05 M
phosphate buffer plus 0.05 sucrose, pH 7.3 overnight at 4 ° C.
Samples were post-fixed in 1% osmium tetroxide, dehydrated,
infiltrated and embedded in Epon. One-micrometer sections were
stained with toluidine blue.
FITC–annexin-V staining
Cells (1 · 106) were resuspended in binding buffer (HEPES-
buffered saline, 5 mM calcium chloride), incubated at 37° C for
15 min with 1 m g ml–1 fluorescein isothiocyanate (FITC)–annexin-
V (R&D Systems) and 5 m g ml–1 propidium iodide, and analysed
by Fluorescence Activated Cell Sorting (FACS, Ortho Clinical
Diagnostics flow cytometer) to determine cell size, annexin
binding and propidium iodide exclusion.
Cell cycle analysis
Cells (1 · 106) were fixed with 70% ethanol for 30 min at 4° C,
incubated with 100 m g ml–1 RNAase and 40 m g ml–1 propidium
iodide in phosphate-buffered saline (PBS) for 30 min at 37° C.
DNA histograms were generated by FACS analysis.
3,3¢ -dihexyloxacarbocyanine iodide (DiOC6(3)) staining
DiOC6(3) staining was used to determine mitochondrial trans-
membrane potential as previously described (Zamzami et al,
1995). A suspension of 1 · 106 cells ml–1 was incubated at 37° C
for 30 min with 50 nM DiOC6(3) and then immediately analysed
by FACS.
Caspase activity
Caspase activity (DEVDase) was determined using a commercial
colorimetric assay (Clontech, USA). Extracts of 2 · 106 cells wereBritish Journal of Cancer (1999) 80(7), 1035–1041incubated for 60 min with aspartate–glutamate–valine–
aspartate–r –nitroanilide (DEVD-r -NA). r -nitroanilide release
following caspase activation was measured by absorbance at
400 nM (Shimadzu spectrophotometer). Background absorbance
was calculated from controls incubated in the absence of substrate.
Magnetic resonance spectroscopy
One to 2 · 108 control and treated cells were extracted using a
modification of the dual-phase extraction method (Ronen et al,
1990; Tyagi et al, 1996). Briefly, a pellet of saline-rinsed L1210
cells or detached SW620 cells was vortexed in 10 ml of ice-cold
methanol, followed by 10 ml of ice-cold chloroform and 10 ml
ice-cold deionized water. For adherent SW620 cells, cells were
rinsed, covered with ice-cold methanol, scraped off the flask
surface, collected and treated as above. Following phase separa-
tion and solvent removal, the water phase was resuspended in D2O
(‘heavy water’, deuterium oxide) with 10 mM EDTA at pH 8.2 and
the lipid phase was resuspended in CDCl3 supplemented with
methanolic EDTA. Samples were stored at –20° C. MRS spectra
were acquired at room temperature on a 250 MHz Bruker spec-
trometer at 101 MHz using a 90° flip angle, a 7 s relaxation delay
and broad-band proton decoupling during acquisition. Metabolite
contents were determined by integration, normalized relative to an
external methylenediphosphonic acid (MDPA) reference peak and
corrected for the number of live cells extracted. NTP content was
calculated from the average of b NTP and g NTP peaks, and
nucleoside diphosphate (NDP) content from b NDP and a NDP.
Due to partial overlap of nicotinamide-adenine dinucleotide
(NAD) and a NTP peaks, NAD/H content was determined by
measuring the total integral and subtracting the contribution of
NTP. To identify the new peaks observed in the spectra of apop-
tosing cells, spectra of candidate metabolites were recorded under
identical conditions as the extracts. Assignments were confirmed
by spiking two treated cell extracts at pH 8.2 and another two
extracts at pH 6.2. Following treatment, in order to separate the
overlapping phosphoethanolamine and fructose 1,6-bisphosphate
(6-P) peaks, the extract pH was acidified from 8.2 to 6.2 using
hydrochloric acid (10 mM).
Results are expressed as mean – s.e.m. and n ‡ 3 unless otherwise
specified. Statistics were performed using a Student’s standard t-test
and differences were assumed to be significant when P < 0.05.
RESULTS
To monitor the progression of apoptosis in L1210 leukaemia cells
treated with 50 m M HN2, different biological markers were moni-
tored over time (Figure 1). We assessed indicators that are associ-
ated with the end stage execution step of apoptosis (Figure 1A)
including DNA fragmentation, phosphatidylserine externalization,
cell size and morphological changes (not shown), as well as
indicators of the earlier stages of the apoptotic process, namely
caspase activation (DEVDase) and loss of mitochondrial trans-
membrane potential (Figure 1B). As illustrated in Figure 1B, we
were able to detect early signs of apoptosis at 4 h following HN2
treatment with the increase in caspase activity to 340% repre-
senting the most significant change at that time.
Extracts from control and HN2-treated L1210 cells were prepared
using a chloroform:methanol:water extract. Representative spectra
obtained from untreated control cells and from cells treated for 3 h
with HN2 are shown in Figure 2. The extract from control cells© 1999 Cancer Research Campaign 
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Figure 1 Time course for 50 m M HN2-treated L1210 cells of (A): (l ) cell
viability, (ss ) presence of hypodiploid cells, (u ) cell size, and (n )
phosphatidylserine externalization. (B): (l ) DiOC6 uptake and (u ) caspase
activation(Figure 2A) showed a similar metabolic profile to previously
published data from L1210 extracts (Berners-Price et al, 1991).
Following-HN2 treatment (Figure 2B), a decrease in nucleotide
signals was observed, as well as the build-up of two prominent
peaks at 4.3 and 4.4 ppm and two smaller peaks at 4.9 and 5.4 ppm.
The identity of the peaks was initially examined by recording 31P
spectra of candidate compounds under the same conditions as the
extracts. The peaks were tentatively identified as fructose 1,6-
bisphosphate (F-1,6-P) at 4.3 (6-P) and 4.4 (1-P) ppm, glycerol-3-
phosphate (G-3-P) at 4.9 ppm and dihydroxyacetone phosphate
(DHAP) at 5.4 ppm. This was confirmed by duplicate experiments
recording a 31P spectrum from an extract of apoptotic cells, spiking
the extract with candidate compounds and confirming that the areas
of the new peaks had increased following spiking. Further confirma-
tion was obtained by acidifying two other extracts to pH 6.2 and
spiking again (at pH 6.2 F-1,6-P resonated at 2.2 and 2.4 ppm, G-3-
P resonated at 2.6 ppm and DHAP at 3.5 ppm).
Figure 2 demonstrates that the increase in F-1,6-P following
HN2 treatment of L1210 cells was very significant, rising from
below detection level (ca. 0.5 fmol cell–1) to a maximum of
30 – 6 fmol cell–1 following 3 h of treatment. G-3-P and DHAP
content was approximately 20% that of F-1,6-P. The time course
for the appearance of F-1,6-P, DHAP and G-3-P is illustrated in
Figure 3A (n = 3–5). F-1,6-P reached a maximum level 3 h post
treatment and declined by 6 h. Interestingly, F-1,6-P, DHAP and
G-3-P could be detected slightly earlier than caspase activation.
As mentioned above there was a decrease in nucleotide content
during apoptosis induced by HN2. The decrease in both
NTP+NDP and NAD was observed within the first hour following© 1999 Cancer Research Campaign drug treatment, with the nucleotides steadily decreasing to below
detection level at 6 h post treatment (P < 0.01 following 3 h of
treatment, Figure 3B). A plot of NTP content alone showed an
identical trend.
The lipid phase of the cell extracts includes the phosphorous-
containing membrane components of the cells and in particular
phosphatidylcholine and sphingomyelin whose degradation might
be involved in signalling during apoptosis. However, the 31P
spectra obtained from the chloroform phase of HN2-treated cells
(data not shown) demonstrated no significant differences from
controls. The phospholipid precursors, phosphocholine and
phosphoethanolamine, which could be detected in the water-
soluble fraction of the extract (Figure 2) decreased slightly during
the first 2 h of treatment and then remained unchanged at 60% –
20% of control (n = 3–5, P < 0.05 for 2 h and P < 0.07 for 3–6 h).
To confirm that our observations were not specific to cell line or
treatment we investigated a second model system. To also confirm
that the MR results were not simply due to cells sustaining drug-
induced DNA damage but were related to the presence of cells
destined to die, we chose the adherent epithelial SW620 colorectal
cell line. Apoptosis was induced by treating with 1 m M doxo-
rubicin. Morphological observation (Figure 4 A, B) indicated that
apoptosis was ultimately detected almost exclusively in the cells
that detached from the surface of the culture flask following treat-
ment and floated in the medium, consistent with earlier studies of
SW620 cells (Hague et al, 1993; Heerdt et al, 1994). This was
confirmed by cell cycle analysis: the presence of hypodiploid cells
was detected exclusively in the population of floating cells. In
duplicate analysis, 20–30% of the floating cells were apoptotic at
8 h, 50–60% at 16 h, and after 24 h of doxorubicin treatment all of
the floating SW620 cells were hypodiploid. Figure 4 also illus-
trates the spectra obtained from adherent control (Figure 4C), as
well as adherent and floating cells following 24 h of doxorubicin
treatment (Figure 4D and 4E respectively). In the attached treated
cells, a 30–40% (n = 2) decrease in NTP content was observed
compared to controls. However, in contrast to L1210 cells treated
with HN2, no new signals could be detected in the attached cell
population following exposure to the chemotherapeutic agent. On
the other hand, in the SW620 floating population, composed of
cells committed to apoptosis, F-1,6-P could be detected by 8 h
following treatment and was clearly visible at 24 h (Figure 4E). In
the floating cells the NTP content had decreased to zero after 24 h
of doxorubicin treatment, and a drop in glycerophosphocholine
was also noted. The presence of a significant amount of UDP-
sugars resonating at a similar chemical shift to NAD prevented the
estimation of changes in NAD.
The appearance of F-1,6-P, DHAP and G-3-P following treat-
ment of L1210 and SW620 cells with agents that result in DNA
damage implied that glycolysis was being modulated. A number of
explanations were possible including inhibition of GAPDH or acti-
vation of F-1,6-P synthesis. F-1,6-P synthesis by phosphofructoki-
nase is regulated by protein kinase C (Eigenbrodt et al, 1994). The
role of protein kinase C activation was examined by preincubating
the cells, prior to application of the apoptotic stimulus, with 100
nM staurosporine (STS), a protein kinase inhibitor with a broad
spectrum of activity (e.g. Mueller et al, 1995). This dose of STS
induced cytostasis, but was not cytotoxic. Following preincubation
with STS, HN2-treated L1210 cells showed the same increase in
glycolytic intermediates as cells treated with HN2 alone (Table 1).
Cells treated with STS alone produced a spectrum identical to
controls.British Journal of Cancer (1999) 80(7), 1035–1041
1038 SM Ronen et al
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Figure 2 1H decoupled 31P MRS spectra of extracts from (A) control L1210 cells, (B) 3 h treated L1210 cells following 3 h of treatment with 50 m M HN2.
Spectra are the result of 10 000 scans plotted with a line broadening of 0.5 Hz
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Figure 3 Time course for 50 m M HN2-treated L1210 cells of (A): (l ) F-1,6-
P, (u ) DHAP, (s ) G-3-P, as detected by MRS and expressed relative to the
average maximum value detected 3 hours post treatment. (B): (l )
NTP+NDP, (s ) NAD, as detected by MRS. Error bars represent s.e.m.
(n ‡ 3). *Indicates a statistically significant difference between treated and
control and P-values were as follows. For NTP+NDP: at 3 h P = 0.0005; at
4.5 h P = 0.0001; at 6 h P = 0.0001. For NAD: at 3 h P = 0.01; at 4.5 h
P = 0.004; at 6 h P = 0.0001To test the hypothesis that the appearance of F-1,6-P, DHAP and
G-3-P was due to inhibition of GAPDH, we used iodoacetate,
shown to specifically inhibit GAPDH at concentrations below
1 mM (Webb, 1966). We treated L1210 cells with 250 m M iodo-
acetate, a dose that had minimal effects on viability (> 95% at
24 h). Following 4 and 8 h of treatment, F-1,6-P signals repre-
senting 3 and 6 fmol cell–1, respectively, could be observed in the
cell extracts, while NTP content dropped to 80% of control (Table
1). G-3-P and DHAP remained below detection level at 4 h and
were on the order of 1 fmol cell–1 at 8 h. This indicated inhibition
of GAPDH.
As mentioned above, NAD levels decreased within an hour
following HN2 treatment of L1210 cells. In addition to being a co-
factor required for GAPDH activity, NAD is also a substrate for
PARP, an enzyme involved in DNA damage repair (Satoh and
Lindahl, 1992). DNA damage induced by either HN2 or doxoru-
bicin could result in PARP activation, leading to the consumption
of NAD, and NAD depletion could in turn result in inhibition of
GAPDH. To test this hypothesis we pretreated the cells with
10 mM 3-aminobenzamide (3-ABA), a competitive inhibitor of
PARP. One hour preincubation of L1210 cells with 10 mM 3-ABA
effectively blocked the cytotoxic effects of HN2 at 24 h,
increasing cell viability from 9% to 82% relative to untreated
control (P < 0.05) and preventing the appearance of hypodiploid
cells as evidenced by FACS. The inhibitor concentration used was
based on previous work (e.g. Milam and Cleaver, 1984), and was
assessed in our system by determining the effects of 1, 5, 10 and 15
mM 3-ABA. The minimum dose of 3-ABA required to signifi-
cantly block the effect of HN2 was 10 mM. Importantly, preincuba-
tion with 10 mM 3-ABA was found to prevent the build-up of
F-1,6-P, DHAP and G-3-P, as well as the decrease in NAD (Table
1). To try and rule out possible non-specific effects of 3-ABA we
also investigated a second PARP inhibitor, nicotinamide, the by
product of ADP-ribose polymerization. Similar to our observations
with 3-ABA, pretreatment with 15 mM nicotinamide also blocked© 1999 Cancer Research Campaign 
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Figure 4 Light microscope images of toluidine blue-stained 1 m m sections
of 24 h doxorubicin-treated SW620 cells (A) adherent population and
(B) detached population (bar represents 10 m m). 1H decoupled 31P MRS
spectra of SW620 cells (C) control adherent, (D) treated adherent population,
(E) treated detached population. Spectra are the result of 10 000 scans
plotted with a line broadening of 0.5 Hz
Table 1 Summary of MRS-detected metabolic changes in L1210 cells
following treatment
Treatment Glycolytic NAD (b) n
intermediates (a)
HN2 (3 h) Ý ß 6
I-acetate › fl 4
STS + HN2 Ý ß 2
STS fi fi 2
Nic + HN2 fi › 4
Nic fi › 1
3-ABA + HN2 fi fi 2
3-ABA fi fi 1
fi unchanged relative to untreated control; (a) Ý observed F-1,6-P, G-3-P
and DHAP, › observed F-1,6-P; (b) fl down to 60–80% of control, ß down to
0% of control, › up 150–200% of control. HN2: mechlorethamine; STS:
staurosporine; Nic: nicotinamide; 3-ABA: 3-aminobenzamide.the appearance of the glycolytic intermediates and prevented the
decrease in NAD in the HN2-treated L1210 cells.
DISCUSSION
In this study, we have used 31P MRS to monitor metabolic changes
which occur in vitro in tumour cells following apoptosis induced by
chemotherapeutic treatment. We have identified the MRS signals
associated with apoptosis in our cells and have compared the
temporal evolution of these signals with the appearance of a
number of known biological markers of apoptosis. In addition, we
have tried to understand the mechanism responsible for the MR-
detectable metabolic changes. The importance of such studies is
twofold: first they can aid in interpreting MRS changes observed in
treated tumours, and second they can contribute to a further under-
standing of some of the steps involved in apoptotic cell death.
Compared to in vitro systems, the number of cells synchro-
nously apoptosing in vivo can be small (Ellis et al, 1997), andBritish Journal of Cancer (1999) 80(7), 1035–1041
1040 SM Ronen et alconsequently MRS changes might be difficult to detect and
interpret without prior knowledge of the likely spectral changes.
Furthermore, the precise identification of new peaks observed in
an in vivo spectrum can often remain uncertain. To avoid these
problems we concentrated on a well-defined model system in
which a relatively large number of cells were induced to undergo
apoptosis simultaneously. In addition, we performed our investiga-
tions on cell extracts, and thus the high spectral resolution and the
ability to manipulate the samples enabled us to unambiguously
identify the MRS changes occurring in apoptosing cells.
Following HN2-treatment, all the L1210 cells ultimately died by
apoptosis. However, at any given time point, it was difficult to
distinguish between cells that had already committed to death and
those that had not. This prevented us addressing the question
whether our MRS observations were a consequence simply of DNA
damage or were correlated with cell death. We therefore also inves-
tigated the adherent SW620 cells. In contrast to L1210 cells, SW620
cells could be separated into adherent cells and cells that detached
from the culture flask following chemotherapeutic treatment. Only
the cells that detached ultimately showed morphological signs of
apoptosis and DNA fragmentation, making it possible to isolate
cells which had committed to apoptosis. The substantial build-up of
glycolytic intermediates observed in detached SW620 cells and
treated L1210 cells, but not in adherent treated SW620 cells, lead us
to conclude that the MRS changes were correlated with commit-
ment to apoptosis. Furthermore, SW620 data also indicated that our
observations were not specific to L1210 cells or HN2-treatment.
The MR detectable changes in NTP, NAD and the glycolytic
intermediates occurred relatively early, with changes in the meta-
bolic profile of L1210 cells treated with HN2 apparent within 2–
3 h following treatment. The increase in glycolytic intermediates
could not simply be ascribed to a small number of apoptotic cells
appearing at 3 h, since the concentrations of glycolytic inter-
mediates did not continue to rise after 3 h when the majority of
apoptotic cells appeared.
NTP decreased steadily following HN2 treatment of L1210
cells. At 3 h, NTP content was 53% of control and dropped to 12%
at 4.5 h and 0% at 6 h (Figure 3B). During this time, plasma
membrane integrity remained at > 98% (Figure 1A). Cell size
decreased to 93% of control at 3 h post treatment, 90% at 4 h, and
76% at 6 h (Figure 1A). Thus, the decrease in cellular energy
content was not due to leakage as a result of damaged plasma
membranes, and could not be explained entirely by cell shrinkage.
HPLC analysis of these cells has shown that over 60% of NTP in
these cells is composed of ATP (Berners-Price et al, 1991). The
drop in NTP content in our cells is therefore most likely to be due
to energy utilization by the cell for apoptosis and is consistent with
earlier reports (Eguchi et al, 1997).
We considered a number of mechanisms to explain the build-up
of glycolytic intermediates in our cells. SW620 cells have a
mutant, non-functional, p53 gene product (O’Connor et al, 1997),
ruling out p53 involvement. One possible explanation of our
results was activation of F-1,6-P synthesis by protein kinase C,
which activates 6-phosphofructo-2-kinase, leading to increased
synthesis of fructose 2,6 bisphosphate, an activator of phospho-
fructokinase (Eigenbrodt et al, 1994). However, preincubation of
L1210 cells with the protein kinase inhibitor staurosporine prior to
HN2 treatment did not prevent F-1,6-P, DHAP and G-3-P build-
up, which were detected at a level comparable to that observed
with HN2 alone. This ruled out involvement of phosphorylation by
protein kinase C in explaining our results.British Journal of Cancer (1999) 80(7), 1035–1041A more likely explanation for the build-up of F-1,6-P together
with DHAP and G-3-P is inhibition of the flux through the
glycolytic pathway at the level of GAPDH. Inhibition of GAPDH
would lead to build-up of glyceraldehyde-3-phosphate and DHAP.
The absence of a detectable glyceraldehyde-3-phosphate peak is
most likely a consequence of the isomerase reaction equilibrium.
Typically, 90% of the triose mixture is present as DHAP and 10%
as glyceraldehyde-3-phosphate (White et al, 1978). Based on the
concentration of DHAP detected in our experiments (up to
6 fmol cell–1), the maximum possible glyceraldehyde-3-phosphate
concentration would therefore be 0.66 fmol cell–1. This was at the
limit of MRS detection level in our system. The equilibrium
constant for the aldolase favours, in the absence of DHAP and
glyceraldehyde-3-phosphate clearance, the synthesis of F-1,6-P
(White et al, 1978), explaining the presence of a relatively high
F-1,6-P concentration. Following iodoacetate treatment, a F-1,6-P
peak could be detected in the cell extracts, and although the inten-
sity of the F-1,6-P peak was not as large as that detected following
HN2-treatment, its appearance did nonetheless indicate that
inhibition of glycolysis at the level of GAPDH was a possible
explanation of our results.
A possible explanation of GAPDH inhibition and the subse-
quent accumulation of glycolytic intermediates was NAD deple-
tion. A reduction in NAD has been reported to inhibit GAPDH as
well as the whole of the glycolytic pathway, with F-1,6-P accumu-
lating in the cell (Eigenbrodt et al, 1994). The decrease in NAD
observed following HN2 treatment could be due to activation of
PARP, which consumes NAD. A substantial drop in NAD levels,
as well as a depletion in ATP following PARP activation, have
been reported in other systems (Satoh and Lindahl, 1992; Martin et
al, 1997). We tested this hypothesis by pre-incubating L1210 cells
with two different PARP inhibitors: 3-ABA, and nicotinamide.
Both inhibitors prevented NAD depletion in our cells and no accu-
mulation of F-1,6-P, G-3-P or DHAP was observed in either case.
PARP inhibition also blocked the cytotoxic effects of HN2 for at
least 24 hours, suggesting a possible link between NAD depletion,
accumulation of glycolytic intermediates and cell death induced
by DNA damage (Nosseri et al, 1994; Zhang et al, 1994).
Furthermore, PARP is proteolytically degraded by caspase 3, but
in our model, the decrease of NAD was observed as early as 1 h
following treatment and well before caspase activation was
apparent (4 h). Nonetheless, one has to treat this explanation with
caution. Apoptosis can occur in the absence of PARP and in some
cases PARP-deficient cells are more sensitive to DNA damage
than wild-type cells (e.g. Lerst et al, 1997). In addition, PARP is a
member of a gene superfamily which are all NAD-metabolizing
enzymes (Koch-Nolte and Haag, 1997) and we can not rule out the
involvement of another such enzyme in explaining our results.
In conclusion, we have shown that, using 31P MRS, we detect an
increase in the glycolytic intermediates F-1,6-P, DHAP and G-3-P
in cells apoptosing following exposure to DNA damaging agents.
This indicated an inhibition of the glycolytic pathway at the level
of GAPDH and could be explained by NAD depletion by PARP.
Interestingly, this inhibition occurred relatively early in the apop-
totic cascade. We speculate that, when DNA damage is substantial
enough to induce apoptosis, the 31P MRS spectrum of treated
tumours could be affected early following treatment, particularly
in the phosphomonoester region where F-1,6-P resonates. We will
be extending our investigations to in vivo models to determine the
possible value of MRS in assessing increased apoptosis in treated
tumours.© 1999 Cancer Research Campaign 
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